Ipsen : Feedback from Q1 2024 webcast
>Slower growth over the coming quarters? - Highlights from yesterday’s meeting:1/ Q1 was a good quarter, but growth in Q1 (+13% cc) seems unlikely to be extrapolated: i/ new generic versions of Somatuline are set to reach Europe and North America in H2 2024/early 2025, ii/ Cabometyx benefited from a cut-off effect, resulting in a favourable cumulative impact of =€ 20me in Q1.Management remains optimistic about Dysport (market share gains and indication exten...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.